Global Rift Valley Fever Virus Nucleic Acid Detection Kit Market Size By Type (Dry PCR, Fluorescence PCR), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

lobal Rift Valley Fever Virus Nucleic Acid Detection Kit Market Report Description

The Global Rift Valley Fever Virus (RVFV) Nucleic Acid Detection Kit Market was valued at USD 221.5 million in 2023 and is projected to reach USD 487.6 million by 2031, growing at a CAGR of 10.3% during the forecast period from 2023 to 2031. The increasing prevalence of zoonotic diseases, growing concerns over emerging infectious threats, and rising governmental and global health agency initiatives to monitor vector-borne outbreaks are significant factors driving market growth. Nucleic acid detection kits are critical tools for early diagnosis, epidemiological surveillance, and outbreak control of Rift Valley Fever Virus, especially in endemic regions such as Africa and parts of the Middle East.

Drivers

1. Surge in Vector-Borne Disease Incidence:

Rising occurrences of mosquito-borne illnesses, including RVF, are creating an urgent need for early and accurate diagnostics. The increased risk of transmission due to climate change, livestock movement, and urbanization contributes significantly to market growth.

2. Government Surveillance Programs & WHO Mandates:

Programs led by WHO, CDC, and national health ministries to monitor and contain vector-borne outbreaks are propelling the demand for high-sensitivity diagnostic kits, including nucleic acid-based tests.

3. Advancements in Molecular Diagnostics:

Technological innovations such as real-time PCR and isothermal amplification techniques have enhanced the sensitivity, speed, and accuracy of RVFV detection kits, making them a preferred choice in clinical and field settings.

Restraints

1. Limited Access in Low-Resource Settings:

High costs of nucleic acid detection kits and lack of laboratory infrastructure in remote and underdeveloped regions pose a challenge to widespread adoption.

2. Regulatory Hurdles and Validation Requirements:

Obtaining approval for new diagnostic kits involves stringent regulatory processes, including clinical validation, which can delay market entry.

Opportunity

1. Growing Demand for Point-of-Care (POC) Molecular Kits:

The expansion of portable and easy-to-use POC RVFV detection kits represents a major opportunity, especially in remote outbreak-prone regions lacking lab infrastructure.

2. Strategic Collaborations and Public Health Funding:

Increased funding for epidemic preparedness and partnerships between diagnostic firms and health agencies are likely to accelerate market development and distribution.

Market by System Type Insights

By system type, RT-PCR based detection kits dominated the market in 2023, holding the largest revenue share. The segment benefits from high accuracy and rapid turnaround times. However, the isothermal nucleic acid amplification kits are expected to witness the highest growth due to their simplicity, cost-effectiveness, and field-deployable capabilities in low-resource environments.

Market by End-use Insights

In terms of end use, public health laboratories and disease control centers emerged as the largest segment in 2023, driven by government-led outbreak tracking initiatives. Meanwhile, the veterinary and agricultural sector is projected to grow significantly during the forecast period, as livestock testing remains crucial to preventing RVFV spillover to human populations.

Market by Regional Insights

Regionally, Africa led the market in 2023, accounting for the largest share due to RVFV’s endemic nature in many African countries and proactive disease control programs. However, the Middle East and Asia-Pacific are poised to grow rapidly, supported by increasing surveillance and healthcare investments in vulnerable zones.

Competitive Scenario

Key players in the Global RVFV Nucleic Acid Detection Kit Market include Roche Diagnostics, Thermo Fisher Scientific, Qiagen N.V., Bio-Rad Laboratories, Meridian Bioscience, Eurofins Scientific, Bioneer Corporation, Genekam Biotechnology AG, and Liferiver Bio-Tech Corp. These companies focus on expanding their molecular diagnostic product lines, obtaining regulatory approvals, and engaging in partnerships with global health organizations.

Recent Developments:

In 2023, Qiagen launched a portable RT-PCR kit for RVFV detection, designed for field deployment in outbreak regions.

In 2024, Bio-Rad Laboratories secured FDA Emergency Use Authorization (EUA) for its high-throughput RVFV nucleic acid test.

In 2025, Liferiver Bio-Tech announced a strategic partnership with African CDC to deploy mobile diagnostic labs across sub-Saharan Africa.

Scope of Work – Global Rift Valley Fever Virus Nucleic Acid Detection Kit Market

Report Metric Details

Market Size (2023) USD 221.5 million

Projected Market Size (2031) USD 487.6 million

CAGR (2023–2031) 10.3%

Market Segments By System Type, End-use, and Region

Growth Drivers Rise in RVF cases, Government Surveillance, Technological Advancements

Opportunities Field-deployable Kits, Emerging Market Expansion

Key Market Developments

2023: Roche Diagnostics developed a dual-target RVFV detection assay that integrates with its cobas® 6800